Incyte Corporation: Melanoma trials

The registry lists 11 Melanoma studies with Incyte Corporation as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 8Phase 2 7Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced MalignanciesCompletedNCT04370704Phase 1/2Results posted
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)CompletedNCT03679767Phase 2Results posted
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
• A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT02923349Phase 1/2Results posted
• A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)CompletedNCT02752074Phase 3Results posted
• A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)CompletedNCT02327078Phase 1/2Results posted
• A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
• Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced MalignanciesCompletedNCT05577182Phase 1
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
• A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
• A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaTerminatedNCT01604889Phase 1/2